Acute myeloid leukemia

2023 - 3 - 3

Post cover — Image courtesy of "Targeted Oncology"

AML Research Continues to Explore Precision Medicine Options (Targeted Oncology)

In an interview with Targeted Oncology, Brian A. Jonas, MD took a close look at the precision medicine landscape for AML and discussed key biomarkers and ...

64 Update on a Phase 1/2 first-in-human study of the Menin-KMT2A (MLL) inhibitor ziftomenib (KO-539) in patients with relapsed or refractory acute myeloid leukemia. Additional approaches to enhance the efficacy and safety of transplant and to maybe expand the number of people that would be able to get by marrow transplant, I think would be a research topic that I would welcome. I think it’s a result of all this effort we put into understanding the biology and the mutational spectrum of the disease now. We still have a long way to go, and I think we're starting to get the tools that we need to have in order to make huge strides. I think the drugs that are very exciting to everyone are things like the drugs that target CD47. One thing it was kind of interesting was it was again, well-tolerated, there were no dose-limiting toxicities and there seems to be a very low rate of mucositis and the MEC arm, which was something that's challenging with MEC. I think my overall message would be we've made huge strides in the last 6 or 7, but we started at a kind of a low bar. With that in mind, a phase 1 clinical trial was started with the combination of this e-selectin inhibitor uproleselan combination with high intensity salvage chemotherapy called MEC, for patients with relapsed/refractory AML. There's been a drug developed to target the e-selectin ligand interaction, it’s a so-called e-selecting antagonist and it's called uproleselan. E-selectin is involved in the bone marrow microenvironment where the hematopoietic stem cells, and the leukemia stem cells are located. “There's been a drug developed to target the e-selectin ligand interaction, it’s a so-called e-selectin antagonist and it's called uproleselan. This progress is due to the knowledge of biomarkers like genetic lesions, mutations, and chromosome abnormalities and how they affect a patient’s disease.

AJMC® in the Press, March 3, 2023 (AJMC.com Managed Markets Network)

Incidences of certain second primary malignancies were associated with increased overall survival among patients with multiple myeloma in a retrospective ...

[Digital Journal](https://www.digitaljournal.com/pr/news/-20b-in-psychiatric-fraud-needs-government-oversight-and-patient-protections) referenced an article published on AJMC.com, the website of AJMC®. [Medical Xpress](https://medicalxpress.com/news/2023-02-notable-inaccuracies-mental-health-directories.html) referenced a study published in the February 2023 issue of The American Journal of Managed Care®(AJMC®). The article, “ [Mental Health Fraud Exacts High Human and Financial Costs](https://www.ajmc.com/view/mental-health-fraud-exacts-high-human-and-financial-costs),” covered the costs of health care fraud and determined that the United States loses approximately $100 billion annually from the practice, of which $20 billion comes from the mental health sector.

S. Korean scientists find gene that can help regulate leukemia ... (Yahoo News)

A team of South Korean researchers has found that a previously discovered gene could regulate the progression of leukemia. Scientists from Pusan National ...

Study Shows Survival Disparities Among Children With ALL Living ... (AJMC.com Managed Markets Network)

Children with acute lymphoblastic leukemia living in US-Mexico border regions had worse 5-year survival rates compared with children living in other parts ...

Of the 1279 children diagnosed with AML, 185 (14.4%) lived in the border region, 93.5% of those living in the border region were Hispanic, and 77.3% lived in high poverty census tracts. Children in the highest poverty level areas were also at a greater risk of death than children in areas with the lowest level of poverty. Among children with ALL, 855 (14.2%) lived in the border region, and 93.8% of children living in the border region were Hispanic. Unadjusted models showed an increased risk of death among children living in border regions, but the adjusted models did not show a statistically significant difference. Non-Hispanic Black children and Hispanic children were also at an increased risk of death compared with non-Hispanic White children in the study. We know there are differences in survival, with children from historically marginalized Hispanic and Black communities faring worse than White children,” study author Maria Castellanos, MD, said in a Among children with AML in border areas, the 5-year survival rate was 53.6% (95% CI, 45.9%-60.73%), while children from non-border areas had a 5-year survival rate of 60.1% (95% CI, 57.0%-63.04%). This highlights a need for incorporating social determinants of health in registries and clinical trials to determine how these factors impact survival outcomes. A total of 6002 children with ALL and 1279 children with AML were included in the analysis. Of those living in the border region, 663 (77.5) lived in higher poverty census tracts. Approximately half of the entire US-Mexico border region is between Texas and Mexico, and this region is medically underserved as well as economically disadvantaged. ALL and AML account for almost 30% of childhood cancer cases, the authors noted.

Expert Outlines KOMET-001 Trial Design Assessing Ziftomenib in AML (Cancer Network)

An expert from Duke Health reviews the design of the phase 1/2 trial of the KOMET-001 study in heavily pretreated patients with relapsed/refractory acute ...